Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells
Open Access
- 9 September 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Pathogens
- Vol. 17 (9), e1009840
- https://doi.org/10.1371/journal.ppat.1009840
Abstract
COVID-19 vaccines based on the Spike protein of SARS-CoV-2 have been developed that appear to be largely successful in stopping infection. However, therapeutics that can help manage the disease are still required until immunity has been achieved globally. The identification of repurposed drugs that stop SARS-CoV-2 replication could have enormous utility in stemming the disease. Here, using a nano-luciferase tagged version of the virus (SARS-CoV-2-ΔOrf7a-NLuc) to quantitate viral load, we evaluated a range of human cell types for their ability to be infected and support replication of the virus, and performed a screen of 1971 FDA-approved drugs. Hepatocytes, kidney glomerulus, and proximal tubule cells were particularly effective in supporting SARS-CoV-2 replication, which is in-line with reported proteinuria and liver damage in patients with COVID-19. Using the nano-luciferase as a measure of virus replication we identified 35 drugs that reduced replication in Vero cells and human hepatocytes when treated prior to SARS-CoV-2 infection and found amodiaquine, atovaquone, bedaquiline, ebastine, LY2835219, manidipine, panobinostat, and vitamin D3 to be effective in slowing SARS-CoV-2 replication in human cells when used to treat infected cells. In conclusion, our study has identified strong candidates for drug repurposing, which could prove powerful additions to the treatment of COVID. The identification of repurposed drugs that stop SARS-CoV-2 replication could have enormous utility in stemming COVID-19. Here, using a nano-luciferase tagged version of the virus (SARS-CoV-2-ΔOrf7a-NLuc) to quantitate viral load, we evaluated a range of human cell types for their ability to be infected and support replication of the virus, and performed a screen of 1971 FDA-approved drugs. Hepatocytes, kidney glomerulus, and proximal tubule cells were particularly effective in supporting SARS-CoV-2 replication, which is in-line with reported proteinuria and liver damage in patients with COVID-19. Using the nano-luciferase as a measure of virus replication we identified 35 drugs that reduced replication in Vero cells and human hepatocytes when treated prior to SARS-CoV-2 infection and found amodiaquine, atovaquone, bedaquiline, ebastine, LY2835219, manidipine, panobinostat, and vitamin D3 to be effective in slowing SARS-CoV-2 replication in human cells when used to treat infected cells. In conclusion, our study has identified strong candidates for drug repurposing, which could prove powerful additions to the treatment of COVID.Keywords
Other Versions
Funding Information
- Wellcome (110126/Z/15/Z)
- Wellcome (203128/Z/16/Z)
- NIHR Manchester Research Centre
- Fungal infection Trust
This publication has 50 references indexed in Scilit:
- Drug repurposing: progress, challenges and recommendationsNature Reviews Drug Discovery, 2018
- The SARS-CoV Fusion Peptide Forms an Extended Bipartite Fusion Platform that Perturbs Membrane Order in a Calcium-Dependent MannerJournal of Molecular Biology, 2017
- Extensive coronavirus-induced membrane rearrangements are not a determinant of pathogenicityScientific Reports, 2016
- Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosisJournal of Hepatology, 2016
- Ultrastructure and Origin of Membrane Vesicles Associated with the Severe Acute Respiratory Syndrome Coronavirus Replication ComplexJournal of Virology, 2006
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003
- A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening AssaysSLAS Discovery, 1999
- Overview of Allergic MechanismsDrugs, 1996
- Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3- hydroxy-1,4-naphthoquinone (566C80)Biochemical Pharmacology, 1992
- The Anti-CD3-Induced Syndrome: A Consequence of Massive In Vivo Cell ActivationCurrent Topics in Microbiology and Immunology, 1991